IL243913A0 - 2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidine-2-ylsulfonylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid - Google Patents
2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidine-2-ylsulfonylmethyl]-4-(trifluoromethoxy)phenyl]boronic acidInfo
- Publication number
- IL243913A0 IL243913A0 IL243913A IL24391316A IL243913A0 IL 243913 A0 IL243913 A0 IL 243913A0 IL 243913 A IL243913 A IL 243913A IL 24391316 A IL24391316 A IL 24391316A IL 243913 A0 IL243913 A0 IL 243913A0
- Authority
- IL
- Israel
- Prior art keywords
- ylsulfanylmethyl
- pyrimidin
- carbamoyl
- fluorophenyl
- phenyl
- Prior art date
Links
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 title 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 title 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/053376 WO2015016938A1 (en) | 2013-08-02 | 2013-08-02 | 2- [5- [n- (4 -fluorophenyl) carbamoyl] pyrimidin- 2 - ylsulfanylmethyl] -4- (trifluoromet hoxy) phenyl] boronic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL243913A0 true IL243913A0 (en) | 2016-04-21 |
Family
ID=48998708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL243913A IL243913A0 (en) | 2013-08-02 | 2016-02-02 | 2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidine-2-ylsulfonylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3027627B1 (enExample) |
| JP (1) | JP6509851B2 (enExample) |
| KR (1) | KR102107372B1 (enExample) |
| CN (2) | CN105683202B (enExample) |
| AU (2) | AU2013395662B2 (enExample) |
| CA (1) | CA2920172C (enExample) |
| DK (1) | DK3027627T3 (enExample) |
| ES (1) | ES2671927T3 (enExample) |
| IL (1) | IL243913A0 (enExample) |
| MX (1) | MX359556B (enExample) |
| NO (1) | NO3027627T3 (enExample) |
| WO (1) | WO2015016938A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3027627B1 (en) * | 2013-08-02 | 2018-01-31 | Syntrix Biosystems Inc. | 2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidin-2-ylsulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| JP2019135244A (ja) * | 2019-04-03 | 2019-08-15 | シントリックス・バイオシステムズ・インコーポレイテッドＳｙｎｔｒｉｘ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． | ２−［５−［ｎ−（４−フルオロフェニル）カルバモイル］ピリミジン−２−イルスルファニルメチル］−４−（トリフルオロメトキシ）フェニル」ボロン酸 |
| CN117954000A (zh) * | 2023-12-29 | 2024-04-30 | 中山大学附属口腔医院 | 用于筛选对治疗牙周炎及认知障碍的化合物的方法及用途 |
| WO2025193763A1 (en) * | 2024-03-12 | 2025-09-18 | Syntrix Biosystems Inc. | Method for increasing survival in patients with cancer |
| EP4686469A1 (en) * | 2024-07-31 | 2026-02-04 | Dompé farmaceutici SpA | Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5475120A (en) | 1990-11-02 | 1995-12-12 | University Of Florida | Method for the isolation and purification of taxol and its natural analogues |
| US5194635A (en) | 1991-03-18 | 1993-03-16 | Virginia Tech Intellectual Properties, Inc. | Rearranged taxol compounds and method of using in testing of in vivo activity |
| US5416225A (en) | 1992-03-30 | 1995-05-16 | Sloan-Kettering Institute For Cancer Research | Total synthesis of taxol |
| US5488116A (en) | 1992-03-30 | 1996-01-30 | Sloan-Kettering Institute For Cancer Research | Total synthesis of taxol and analogues thereof |
| WO1993021173A1 (en) | 1992-04-17 | 1993-10-28 | Abbott Laboratories | Taxol derivatives |
| US5440057A (en) | 1993-08-20 | 1995-08-08 | The Scripps Research Institute | Access to taxol analogs |
| US5461169A (en) | 1992-06-23 | 1995-10-24 | The Scripps Research Institute | Total synthesis of taxol and taxol analogs |
| WO1994005282A1 (en) | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Water soluble taxol derivatives |
| US5478854A (en) | 1992-10-01 | 1995-12-26 | Bristol-Myers Squibb Company | Deoxy taxols |
| US5411984A (en) | 1992-10-16 | 1995-05-02 | Virginia Tech Intellectual Properties, Inc. | Water soluble analogs and prodrugs of taxol |
| CA2126698A1 (en) | 1992-12-07 | 1994-06-23 | Muraleedharan G. Nair | Process for the isolation and purification of taxol and taxanes from taxus spp. |
| US5468769A (en) | 1993-07-15 | 1995-11-21 | Abbott Laboratories | Paclitaxel derivatives |
| FR2707642B1 (fr) | 1993-07-16 | 1995-10-13 | Electricite De France | Dérivés de polyéthers et d'hétérocycles pentacycliques, leurs polymères et leurs applications, notamment à la complexation d'ions métalliques. |
| US5405972A (en) | 1993-07-20 | 1995-04-11 | Florida State University | Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes |
| US5565478A (en) | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
| US5508447A (en) | 1994-05-24 | 1996-04-16 | Board Of Regents, The University Of Texas System | Short synthetic route to taxol and taxol derivatives |
| US5489589A (en) | 1994-12-07 | 1996-02-06 | Bristol-Myers Squibb Company | Amino acid derivatives of paclitaxel |
| SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| EP2942346B1 (en) * | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
| AU2011293612B2 (en) * | 2010-08-23 | 2015-11-26 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
| EP3027627B1 (en) * | 2013-08-02 | 2018-01-31 | Syntrix Biosystems Inc. | 2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidin-2-ylsulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid |
-
2013
- 2013-08-02 EP EP13750432.0A patent/EP3027627B1/en active Active
- 2013-08-02 DK DK13750432.0T patent/DK3027627T3/en active
- 2013-08-02 CN CN201380080028.4A patent/CN105683202B/zh active Active
- 2013-08-02 KR KR1020167005561A patent/KR102107372B1/ko active Active
- 2013-08-02 CA CA2920172A patent/CA2920172C/en active Active
- 2013-08-02 NO NO13750432A patent/NO3027627T3/no unknown
- 2013-08-02 WO PCT/US2013/053376 patent/WO2015016938A1/en not_active Ceased
- 2013-08-02 AU AU2013395662A patent/AU2013395662B2/en active Active
- 2013-08-02 ES ES13750432.0T patent/ES2671927T3/es active Active
- 2013-08-02 JP JP2016531596A patent/JP6509851B2/ja active Active
- 2013-08-02 MX MX2016001490A patent/MX359556B/es active IP Right Grant
- 2013-08-02 CN CN201910299619.XA patent/CN110200979A/zh active Pending
-
2016
- 2016-02-02 IL IL243913A patent/IL243913A0/en unknown
-
2019
- 2019-06-05 AU AU2019203931A patent/AU2019203931B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105683202B (zh) | 2019-05-10 |
| JP2016525573A (ja) | 2016-08-25 |
| CN110200979A (zh) | 2019-09-06 |
| JP6509851B2 (ja) | 2019-05-08 |
| KR102107372B1 (ko) | 2020-05-07 |
| KR20160051765A (ko) | 2016-05-11 |
| MX359556B (es) | 2018-10-02 |
| CA2920172C (en) | 2020-03-10 |
| AU2019203931A1 (en) | 2019-06-27 |
| ES2671927T3 (es) | 2018-06-11 |
| WO2015016938A1 (en) | 2015-02-05 |
| MX2016001490A (es) | 2017-01-05 |
| CA2920172A1 (en) | 2015-02-05 |
| DK3027627T3 (en) | 2018-05-22 |
| AU2013395662A1 (en) | 2016-03-10 |
| EP3027627B1 (en) | 2018-01-31 |
| AU2013395662B2 (en) | 2019-03-14 |
| CN105683202A (zh) | 2016-06-15 |
| EP3027627A1 (en) | 2016-06-08 |
| AU2019203931B2 (en) | 2020-06-11 |
| NO3027627T3 (enExample) | 2018-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284773A (en) | Rna-guided transcriptional regulation | |
| LTC2731935I2 (lt) | Fungicidiniai pakeistieji 2-[2-halogenalkil-4-(fenoksi)-fenil]-1-[1,2,4]triazol-1-il-etanolio junginiai | |
| CL2014003498A1 (es) | Carboxamidas heterocíclicas fungicidas | |
| HRP20181937T1 (hr) | Amidom-supstituirani heterociklični spojevi korisni kao modulatori il-12,il-23 i/ili ifn-alfa | |
| PT2987791T (pt) | Derivado de ácido 3-(4-(benziloxi)fenil)hex-4-inoico, adequado para prevenção e tratamento de doenças metabólicas. | |
| DK2657233T3 (da) | 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf | |
| DK2988743T3 (da) | Heterocykliske forbindelser, der kan anvendes til behandling af sygdom | |
| ME03359B (me) | 2 suptiтuisana cefemska jedinjenja | |
| LT2806859T (lt) | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzenkarboksirūgšties kompozicijos | |
| DK3686194T3 (da) | 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser | |
| EP2714059A4 (en) | TREATMENT OF PAIN USING PLACENTARIAN STEM CELLS | |
| FR3011882B1 (fr) | Boitier d'entrainement d'accessoires pour turbomachine | |
| HRP20191368T1 (hr) | Alkil-amid supstituirani piridil spojevi korisni kao modulatori il-12, il-23 i/ili ifnalfa odgovora | |
| IL259824B (en) | History of 2-[3-(azolyl)phenyl]-3,1-thiazole-5-carboxylic acid for use as drugs | |
| FR2988609B1 (fr) | Formulation pour l'hormonotherapie | |
| SG11201506093SA (en) | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | |
| CL2014003459A1 (es) | Compuestos fungicidas heterocíclicos. | |
| EP2967001A4 (en) | Improved equine hoof boot | |
| CL2014002034A1 (es) | Compuestos derivados de isoxazol-fenil-azetidina fenil sustituidos; y compuestos intermediarios. | |
| EP3041354A4 (en) | Substituted hydroxamic acid compounds | |
| EP2865667A4 (en) | AMID CONNECTION AND USE THEREOF FOR PEST CONTROL | |
| EP2970112A4 (en) | Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same | |
| HRP20181799T1 (hr) | Optimizirana farmaceutska formula, namijenjena liječenju upalnih promjena jednjaka | |
| IL245167A0 (en) | Slow-release solid oral compositions | |
| GB201314518D0 (en) | Horseshoe for laminitis |